FDA Clearance Tracker · P010029-S008
EUFLEXXA (1% SODIUM HYALURONATE)
Last checked: Nov 20, 2026Latest source record: Oct 11, 2011 (this decision)Source: openFDAMethods & limitations
Decided
Oct 11, 2011
Approved
Time to decision
925 days
Received Mar 30, 2009. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P010029-S008
- Device name
- EUFLEXXA (1% SODIUM HYALURONATE)
- Applicant
- Ferring Pharmaceuticals, Inc.
- Applicant location
- Parsippany, NJ
- Received
- Mar 30, 2009
- Decided
- Oct 11, 2011
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P010029
Device type
- Device type
- Acid, hyaluronic, intraarticular (MOZ)
- Device class
- Class III
- Specialty
- Orthopedic Surgery
FDA's approval statement
As written in FDA's record.
APPROVAL FOR EUFLEXXA (1% SODIUM HYALURONATE). THIS DEVICE IS INDICATED FOR THE TREATMENT OF PAIN IN OSTEOARTHRITIS (OA) OF THE KNEE IN PATIENTS WHO HAVE FAILED TO RESPOND ADEQUATELY TO CONSERVATIVENON-PHARMACOLOGIC THERAPY AND TO SIMPLE ANALGESICS (E.G., ACETAMINOPHEN).
Source documents
Other decisions for Ferring Pharmaceuticals, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.